Gedea Biotech announces the start of the clinical study VVC2025—first patients enrolled
PRESS RELEASE Gedea Biotech today announced the start of the clinical study VVC2025, following approval from the Swedish Medical Products Agency (Läkemedelsverket). The randomized and controlled study evaluates Gedea’s product pHyph for the relief of signs and symptoms of vulvovaginal candidiasis…
